Company Profile
Hualan Biological Engineering researches, develops, produces, and sells biological products in China and globally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use
Intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications Vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines.
Additionally, it develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Its portfolio also includes adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases, denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases, injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer, and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes.
It also is involved in the R&D of poultry farming. Its portfolio also includes plasma collection, engineering technology research and experimental development, and inspection and testing services. Founded in 1992, the company is headquartered in Xinxiang, China.